Document is current
Any future updates will be listed below
-
Authors
Gumpper, Ryan H. https://orcid.org/0000-0003-1309-3069
Jain, Manish K. https://orcid.org/0000-0001-8173-3326
Kim, Kuglae
Sun, Renhong
Sun, Ning
Xu, Zhongli
DiBerto, Jeffrey F.
Krumm, Brian E. https://orcid.org/0000-0001-6039-4767
Kapolka, Nicholas J.
Kaniskan, H. Ümit https://orcid.org/0000-0001-5327-832X
Nichols, David E.
Jin, Jian https://orcid.org/0000-0002-2387-3862
Fay, Jonathan F. https://orcid.org/0000-0003-1822-2384
Roth, Bryan L. https://orcid.org/0000-0002-0561-6520
-
Funding
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-20-2-0029)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R37DA045657)
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 6 March 2025
First Online: 19 March 2025
Competing interests
: R.H.G is an active consultant for 2A Biosciences. B.L.R. is a member of the SAB for Onsero, Escient, Septerna, Epiodyne, and Levator. J.J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received or has received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc., and Cullinan Oncology, Inc. D.E.N. is a founder of 2A Biosciences. The remaining authors declare no competing interests.
